This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Clioquinol
Description: PBT-1 is a copper/zinc-binding drug. In preclinical studies, PBT-1 markedly reduced Alzheimer brain pathology in mice within nine weeks. Beta-amyloid accumulation decreased by 50% during that period. This breakthrough provides a viable explanation for the abnormal binding of these metals with beta-amyloid that is commonplace in Alzheimer's disease. The reaction ultimately leads to the corruption of the protein and its ensuing toxicity. Copper and Zinc are normally present at high concentrations in the regions of the brain that are most affected by Alzheimer's disease damage.
Pink Sheet Prana discontinues PBT1 development
Additional information available to subscribers only: